XML 29 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 03, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-38599    
Entity Registrant Name Aquestive Therapeutics, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 82-3827296    
Entity Address, Address Line One 30 Technology Drive    
Entity Address, City or Town Warren    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07059    
City Area Code 908    
Local Phone Number 941-1900    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol AQST    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction false    
Entity Public Float     $ 207.3
Entity Common Stock, Shares Outstanding   98,871,369  
Entity Central Index Key 0001398733    
Amendment Flag false    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Documents Incorporated by Reference
The registrant intends to file a definitive proxy statement pursuant to Regulation 14A in connection with its 2025 Annual Meeting of Shareholders within 120 days of the end of its fiscal year ended December 31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.